Opinion
Video
Management Insights for Patients With Hemophilia
Russell P. Gollard, MD, FACP, discusses hemophilia patients in their plan, identifying these patients, and treatment with newer monoclonal factor products.
Russell P. Gollard, MD, FACP: We have approximately 3 dozen patients in our plan with hemophilia A. Many of those patients present with either a family history or with a proclivity toward bleeding. In young people with severe disease, OOftentimes, this will be something that’s identified at birth when the umbilicus is cut. Other than that, we see playground injuries. We see epistaxis quite often. In young ladies, we will oftentimes see some excessive menstruation. Now, I should say that as this is a sex-linked disease, it’s much more common in males than in females, but there are women with the disease.
In our plan, we manage treatments for rare diseases. These patients are not referred out of state. We are in Las Vegas, Nevada. There is a hemophilia treatment center here that we work with, but we also manage those patients through our own clinics. These patients need to be identified and followed. They are seen in the clinic with some frequency. In some cases, they’re seen at a hemophilia treatment center where there is a full-time nurse practitioner practicing. Many of these patients are very, very active in the management of their own disease and know how to prophylax themselves. Usually, patients get 1 of the newer monoclonal factor 8 products, and these are then given with some frequency, sometimes 3 times a week, sometimes less, depending on the severity of the disease and its penetrance in these patients.
Transcript is AI generated and reviewed by an AJMC editor.
